niacinamide has been researched along with Thrombopenia in 12 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In our patients, nicotinamide effectively decreased phosphorus, increased high-density lipoprotein, and caused thrombocytopenia." | 9.15 | Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial. ( Abbaspour, MR; Belladi Musavi, SS; Ghorbani, A; Hayati, F; Lashkarara, GR; Shahbazian, H; Zafar Mohtashami, A, 2011) |
| "To observe the efficacy and side effects of transarterial chemoembolization (TACE) combined with sorafenib for advanced hepatocellular carcinoma (HCC)." | 9.14 | [Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma]. ( Chen, H; Chen, Z; Lin, JH; Liu, LM; Meng, ZQ; Xu, LT; Zhou, ZH, 2010) |
| "Sorafenib was recently approved for the treatment of these patients." | 5.42 | Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer. ( Abelleira, E; Cross, G; Jerkovich, F; Pitoia, F; Urciuoli, C, 2015) |
| "In our patients, nicotinamide effectively decreased phosphorus, increased high-density lipoprotein, and caused thrombocytopenia." | 5.15 | Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial. ( Abbaspour, MR; Belladi Musavi, SS; Ghorbani, A; Hayati, F; Lashkarara, GR; Shahbazian, H; Zafar Mohtashami, A, 2011) |
| "To observe the efficacy and side effects of transarterial chemoembolization (TACE) combined with sorafenib for advanced hepatocellular carcinoma (HCC)." | 5.14 | [Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma]. ( Chen, H; Chen, Z; Lin, JH; Liu, LM; Meng, ZQ; Xu, LT; Zhou, ZH, 2010) |
| " However, niacin can cause flushing and niacinamide probably cause thrombocytopenia." | 4.90 | Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis. ( Feng, L; He, YM; Huo, DM; Liao, YH; Yang, ZH, 2014) |
| "Hepatocellular carcinoma (HCC) is increasing in numbers worldwide, and no effective systemic treatment existed for advanced HCC until SHARP (Sorafenib in HCC Assessment Randomized Protocol) study proved sorafenib (Nexavar((R)), Bayer Pharmaceuticals, Wayne, NJ, USA) prolonged survival versus placebo." | 3.76 | Platelet count less than SHARP: what does a case series reveal? ( Saif, MW, 2010) |
| " No significant drug-drug interactions were observed." | 2.90 | A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours. ( de Jonge, M; de Weger, VA; Demers, B; Deutsch, E; Goodstal, S; Hsu, K; Langenberg, MHG; Lolkema, M; Macé, S; Schellens, JHM; Thomas, K; Tuffal, G; Varga, A, 2019) |
| " Common adverse events (AEs) were also studied." | 2.52 | Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. ( Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L, 2015) |
| "Sorafenib was recently approved for the treatment of these patients." | 1.42 | Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer. ( Abelleira, E; Cross, G; Jerkovich, F; Pitoia, F; Urciuoli, C, 2015) |
| " Their baseline characteristics, radiologic response, adverse events, and survival status were assessed." | 1.38 | Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. ( Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Kim, TW; Lee, JL; Park, I; Park, K; Park, S; Song, C, 2012) |
| "Temsirolimus appears to be an effective and well-tolerated substance in the treatment of patients with a good performance status, low MSKCC score and stable disease under previous antiangiogenic treatment in advanced renal cell cancer." | 1.37 | Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer. ( Greil, R; Grundbichler, M; Kappacher, A; Mlineritsch, B; Moik, M; Ressler, S; Rosenlechner, S, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 11 (91.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, W | 1 |
| Yuan, YC | 1 |
| Li, MY | 1 |
| Kong, W | 1 |
| Dong, BJ | 1 |
| Chen, YH | 1 |
| Zhang, J | 1 |
| Xue, W | 1 |
| Huang, YR | 1 |
| Zhou, LX | 1 |
| Huang, JW | 1 |
| de Weger, VA | 1 |
| de Jonge, M | 1 |
| Langenberg, MHG | 1 |
| Schellens, JHM | 1 |
| Lolkema, M | 1 |
| Varga, A | 1 |
| Demers, B | 1 |
| Thomas, K | 1 |
| Hsu, K | 1 |
| Tuffal, G | 1 |
| Goodstal, S | 1 |
| Macé, S | 1 |
| Deutsch, E | 1 |
| He, YM | 1 |
| Feng, L | 1 |
| Huo, DM | 1 |
| Yang, ZH | 1 |
| Liao, YH | 1 |
| Hong, S | 1 |
| Tan, M | 1 |
| Wang, S | 1 |
| Luo, S | 1 |
| Chen, Y | 1 |
| Zhang, L | 1 |
| Pitoia, F | 1 |
| Abelleira, E | 1 |
| Jerkovich, F | 1 |
| Urciuoli, C | 1 |
| Cross, G | 1 |
| Saif, MW | 1 |
| Panuganti, S | 1 |
| Papoutsakis, ET | 1 |
| Miller, WM | 1 |
| Xu, LT | 1 |
| Chen, Z | 1 |
| Lin, JH | 1 |
| Zhou, ZH | 1 |
| Chen, H | 1 |
| Meng, ZQ | 1 |
| Liu, LM | 1 |
| Shahbazian, H | 1 |
| Zafar Mohtashami, A | 1 |
| Ghorbani, A | 1 |
| Abbaspour, MR | 1 |
| Belladi Musavi, SS | 1 |
| Hayati, F | 1 |
| Lashkarara, GR | 1 |
| Grundbichler, M | 1 |
| Mlineritsch, B | 1 |
| Ressler, S | 1 |
| Moik, M | 1 |
| Kappacher, A | 1 |
| Rosenlechner, S | 1 |
| Greil, R | 1 |
| Lee, JL | 1 |
| Park, I | 1 |
| Park, K | 1 |
| Park, S | 1 |
| Ahn, Y | 1 |
| Ahn, JH | 1 |
| Kim, TW | 1 |
| Ahn, S | 1 |
| Song, C | 1 |
| Hong, JH | 1 |
| Kim, CS | 1 |
| Ahn, H | 1 |
| Rottembourg, JB | 1 |
| Launay-Vacher, V | 1 |
| Massard, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Study of Combination Therapy With SAR405838 and Pimasertib in Patients With Advanced Cancer[NCT01985191] | Phase 1 | 26 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for niacinamide and Thrombopenia
| Article | Year |
|---|---|
Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis.
Topics: Flushing; Humans; Lipoproteins, HDL; Niacin; Niacinamide; Phosphorus; Randomized Controlled Trials a | 2014 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2015 |
3 trials available for niacinamide and Thrombopenia
| Article | Year |
|---|---|
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Femal | 2019 |
[Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoe | 2010 |
Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial.
Topics: Administration, Oral; Adult; Aged; Diarrhea; Double-Blind Method; Female; Humans; Hyperglycemia; Hyp | 2011 |
7 other studies available for niacinamide and Thrombopenia
| Article | Year |
|---|---|
[Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Disease-Free Survival; | 2018 |
Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer.
Topics: Aged; Antineoplastic Agents; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinami | 2015 |
Platelet count less than SHARP: what does a case series reveal?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver | 2010 |
Bone marrow niche-inspired, multiphase expansion of megakaryocytic progenitors with high polyploidization potential.
Topics: Antigens, CD34; Blood Platelets; Bone Marrow; Cell Culture Techniques; Cell Differentiation; Cell Li | 2010 |
Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Proto | 2011 |
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenes | 2012 |
Thrombocytopenia induced by nicotinamide in hemodialysis patients.
Topics: Humans; Kidney Failure, Chronic; Niacinamide; Phosphorus; Renal Dialysis; Thrombocytopenia; Vitamin | 2005 |